BlueTechBio unlocks the pharmacology of marine biodiversity to build a new generation of precision peptide therapeutics.
We uncover the hidden biodiversity from underwater life.
We harness the power of artificial intelligence to move with speed and judgment.
We develop tomorrow's medicines.
Despite decades of innovation, many diseases remain difficult to treat. Nature has already evolved solutions that pharmaceutical research has barely explored.
Still relies heavily on opioids.
Many cancers still lack effective therapies.
Antimicrobial resistance rises.
Treatment options are limited.
We combine rare biological access with artificial intelligence and rigorous drug discovery science to move faster than traditional approaches allow.
We access sources of marine biodiversity that remain largely unexplored by pharmaceutical research.
Artificial intelligence helps us screen and rank candidate molecules with speed and judgment.
Promising candidates advance through rigorous preclinical science, in collaboration with academic and research partners.
Permissioned access to sources of marine biodiversity under international frameworks.
Machine learning helps us move from raw biodiversity to promising candidates faster.
Collaborations with academic and research institutions strengthen validation at every stage.
Deep operational and scientific expertise built over years in the field.
We believe the ocean holds a vast, underexplored source of therapeutic biology. By combining rare biological access, artificial intelligence, and rigorous drug discovery science, BlueTechBio is building a pipeline of peptide-based medicines for conditions where patients still lack good options.
BlueTechBio